18P In vitro analysis of the combination of APR-246 and carboplatin in triple negative breast cancer (TNBC) and high grade serous ovarian cancer (HGSOC) cell lines and its impact on Aurora kinase A (AURKA)-p53 pathway

Incidence of oncogenes in PI3K/AKT and MAPK signaling pathways in breast cancer

Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines

Extravasation is the process by which any liquid (fluid or drug) accidentally leaks into the surrounding tissue. In terms of cancer therapy, extravasation refers to the inadvertent infiltration of chemotherapy into the subcutaneous or subdermal tissues surrounding the intravenous or intra-arterial administration site. Extravasated drugs are classified according to their potential for causing damage as ‘vesicant’, ‘irritant’ and ‘nonvesicant’ (Table 1). Some vesicant drugs are further classified into two groups: DNA binding and non-DNA binding. Allwood et al. (2002) divided the drugs into vesicants, exfoliants, irritants, inflammitants and neutrals.

No effect of length time bias on the genomic risk in ER+ HER2-stage I-IIA breast cancer (BC) patients according to diagnosis in a screening programme: An exploratory analysis

Association of the rs4567312 variant in the leptin receptor gene with plasma leptin concentrations and lung cancer incidence in the PREDIMED study

Intraperitoneal chemotherapy (IP CT) after cytoreductive surgery benefits survival in epithelial ovarian cancer (EOC): Results of a pooled meta-analysis including 9 randomized clinical trials (RCT)